
Quarterly report 2025-Q3
added 11-03-2025
Boston Scientific Corporation Net Income 2011-2026 | BSX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Boston Scientific Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.85 B | 1.59 B | 698 M | 1.04 B | -82 M | 4.7 B | 1.67 B | 104 M | 347 M | -239 M | -119 M | -121 M | -4.07 B | 441 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.7 B | -4.07 B | 558 M |
Quarterly Net Income Boston Scientific Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 755 M | 795 M | 672 M | 468 M | 322 M | 493 M | 504 M | 270 M | 314 M | - | 188 M | 260 M | 110 M | - | 419 M | 186 M | 341 M | - | -155 M | -147 M | 11 M | - | 126 M | 154 M | 424 M | - | 432 M | 555 M | 298 M | - | 283 M | 146 M | 290 M | - | 228 M | -207 M | 202 M | - | -198 M | 102 M | -1 M | - | 43 M | 4 M | 133 M | - | -5 M | 130 M | -354 M | - | -664 M | -3.58 B | 113 M | - | 142 M | 146 M | 46 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 795 M | -3.58 B | 107 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | ||
|
AxoGen
AXGN
|
-9.96 M | $ 30.83 | -0.32 % | $ 1.36 B | ||
|
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | ||
|
Abiomed
ABMD
|
226 M | - | - | $ 17.2 B | ||
|
Cognyte Software Ltd.
CGNT
|
-12.1 M | $ 9.3 | -3.23 % | $ 668 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 41.91 | 4.76 % | $ 1.29 B | ||
|
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | ||
|
Apyx Medical Corporation
APYX
|
-18.7 M | $ 3.87 | -0.26 % | $ 134 M | ||
|
Alphatec Holdings
ATEC
|
-162 M | $ 15.99 | -2.8 % | $ 2.29 B | ||
|
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | ||
|
Bio-Rad Laboratories
BIO
|
-716 M | $ 317.35 | -1.51 % | $ 8.95 B | ||
|
EDAP TMS S.A.
EDAP
|
-19 M | $ 4.0 | -2.2 % | $ 149 M | ||
|
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | ||
|
Bruker Corporation
BRKR
|
113 M | $ 49.4 | -2.91 % | $ 7.36 K | ||
|
BioSig Technologies
BSGM
|
-10.3 M | - | 37.08 % | $ 85.7 M | ||
|
Abbott Laboratories
ABT
|
13.4 B | $ 124.69 | 0.35 % | $ 217 B | ||
|
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | ||
|
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | ||
|
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
-6.94 M | $ 12.46 | 0.97 % | $ 960 M | ||
|
Zynex
ZYXI
|
2.99 M | - | - | $ 21.1 M | ||
|
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | ||
|
IRIDEX Corporation
IRIX
|
-9.57 M | $ 1.32 | -4.35 % | $ 21.3 M | ||
|
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | ||
|
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
7.54 M | $ 28.27 | 1.0 % | $ 239 M | ||
|
Pulmonx Corporation
LUNG
|
-56.4 M | $ 2.0 | 2.56 % | $ 78.2 M | ||
|
InMode Ltd.
INMD
|
181 M | $ 14.05 | 0.14 % | $ 1.11 B | ||
|
Second Sight Medical Products
EYES
|
-23.5 M | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
421 M | $ 169.61 | -0.35 % | $ 12.7 B | ||
|
Accuray Incorporated
ARAY
|
-1.59 M | $ 0.84 | -2.44 % | $ 86.3 M | ||
|
IRadimed Corporation
IRMD
|
19.2 M | $ 101.77 | 2.54 % | $ 1.29 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-37.8 M | $ 18.52 | -0.94 % | $ 427 M | ||
|
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
-18.9 M | $ 15.46 | 6.81 % | $ 418 M | ||
|
FONAR Corporation
FONR
|
12.4 M | $ 18.61 | 0.08 % | $ 122 M | ||
|
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | ||
|
Myomo
MYO
|
-10.7 M | $ 0.92 | -2.58 % | $ 6.49 M | ||
|
Orthofix Medical
OFIX
|
-126 M | $ 14.38 | -2.94 % | $ 548 M |